Sen. Marco Rubio (R-FL) and Sen. Angus King (I-ME) (Photo by Anthony Behar/Sipa USA)(Sipa via AP Images) (Graeme Sloan/Sipa USA)(Sipa via AP Images)

September 18, 2024 11:11 AM EDTUpdated 01:08 PM

FDA+

Manufacturing

Senators tell FDA that ‘greater action is needed’ to use manufacturing tech in US supply chains

Anna Brown

News Reporter

Sens. Marco Rubio (R-FL) and Angus King (I-ME) have told the FDA that “considerable work” needs to be done to address how advanced manufacturing technologies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senators tell FDA that ‘greater action is needed’ to use manufacturing tech in US supply chains

Anna Brown

News Reporter

Sign up to read this article for free.

Stem cell startup spun out of George Church’s lab raises $75M

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Upstream Bio files for IPO in sign of life for biotech public offerings

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Breaking down silos with a new quantitative approach to drug development

Sen­a­tors tell FDA that ‘greater ac­tion is need­ed’ to use man­u­fac­tur­ing tech in US sup­ply chains

Anna Brown

News Reporter

Sign up to read this article for free.

Stem cell start­up spun out of George Church’s lab rais­es $75M

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Senators tell FDA that ‘greater action is needed’ to use manufacturing tech in US supply chains

Stem cell startup spun out of George Church’s lab raises $75M

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Upstream Bio files for IPO in sign of life for biotech public offerings

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Breaking down silos with a new quantitative approach to drug development